Article Details
Retrieved on: 2021-08-23 15:33:45
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Wainwright has a Buy rating and a $25 per share price target on Galmed Pharmaceuticals. This target implies a significant potential return, as the biopharma's ...
Article found on: www.streetwisereports.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here